Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Journal of translational medicine - 17 Sept 2013

Peacock Jacqueline D, Cherba David, Kampfschulte Kevin, Smith Mallory K, Monks Noel R, Webb Craig P, Steensma Matthew

Abstract excerpt

BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) are rare highly aggressive sarcomas that affect 8-13% of people with neurofibromatosis type 1. The prognosis for patients with MPNST is very poor. Despite TOP2A overexpression in these tumors, doxorubicin resistance is common, and the m...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Damage
Share to Doxorubicin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Multidrug Resistance-Associated Proteins

Share to Nerve Sheath Neoplasms

Share to Oligonucleotide Array Sequence Analysis

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 24040940
DOI: 10.1186/1479-5876-11-213
PMCID: PMC3848568

Genes

ABCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24040940-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.PMID 24040940Read ↗

Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosisSemantic proximity Read ↗

A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for TreatmentSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Systemic Options for Malignant Peripheral Nerve Sheath Tumors.Semantic proximity Read ↗

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.Semantic proximity Read ↗

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.Semantic proximity Read ↗

Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q statusSemantic proximity Read ↗

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.Semantic proximity Read ↗

Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targetsSemantic proximity Read ↗

Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identitiesSemantic proximity Read ↗

Integrated <i>ex vivo</i> screening and transcriptomic profiling to prioritize drug combinations for rare cancersSemantic proximity Read ↗

DNA-Based Deep Learning and Association Studies for Drug Response Prediction in LeiomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.